Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

New vaccine for cattle pneumonia

CSIRO : 15 October, 2006  (New Product)
A vaccine for a major bacterial cattle disease, bovine respiratory disease, which currently costs the Australian feedlot industry around $60m a year, is now available in Australia.
Developed by CSIRO Livestock Industries and the Cooperative Research Centre for Cattle and Beef Quality, the vaccine (Bovilis MH) is being manufactured and marketed by one of the world's largest veterinary products companies, Intervet.

The first vaccine of its kind to be made available in Australia, Bovilis MH will reduce the use of antibiotics and anti-inflammatory drugs currently used in the treatment of BRD.

CSIRO Livestock Industries project leader, Dr Chris Prideaux, says BRD is caused by a variety of factors.

'The disease, also known as 'shipping fever', is a complex form of pneumonia in which viruses can predispose an animal to bacterial infection.'

'It can manifest when cattle stress levels are raised and this is when their immune status is compromised,' Dr Prideaux says.

The vaccine, Bovilis MH, provides protection against Mannheimia haemolytica, the main bacterial pathogen associated with BRD.

'This is the first time that we have a vaccine that tackles Mannheimia haemolytica and also immunises cattle against leukotoxin,' Dr Prideaux says.

According to Intervet Australia's R&D and Regulatory Affairs Manager, Dr Neil Sammons, Bovilis MH is one of a suite of cattle and pig vaccines the company is developing for Australian producers.

'The product is highly competitive for the Australian market, and producers using it should expect immediate and significant productivity savings,' Dr Sammons says.

He says the vaccine will also improve the general welfare of cattle kept under intensive management systems.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo